Bionano Genomics, Inc. 8-K

What Happened

• On May 13, 2026, Bionano Genomics, Inc. announced and furnished a press release reporting its financial results for the first quarter ended March 31, 2026. The press release is attached to the Current Report on Form 8-K as Exhibit 99.1.
• The Form 8-K was signed by Interim Chief Executive Officer Albert A. Luderer, Ph.D. The filing furnishes the quarterly results to the market (Item 2.02).

Key Details

• Filing date: May 13, 2026.
• Quarter reported: Q1 2026, period ended March 31, 2026.
• Exhibit included: 99.1 — press release announcing the quarterly financial results. (Cover page Inline XBRL is included as Exhibit 104.)
• The 8-K covers results disclosure only (Item 2.02); it does not report management changes or corporate transactions in this filing.

Why It Matters

• Quarterly financial results (earnings, revenue, cash position, and any guidance) are material to investors because they directly affect valuation, investor expectations, and near-term stock performance.
• Retail investors should read the attached press release for the specific financial metrics and management commentary to assess revenue trends, profitability, cash runway, and any guidance or outlook provided.
• Because this 8-K only furnishes the press release, any material changes beyond the disclosed results would appear in subsequent filings or releases.